{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000148","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.926565+00:00","generated_at":"2026-05-17T03:02:10.646213+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger","bullets":["Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.","Bonus payable upon closing of the previously announced merger with Decoy Therapeutics.","Payment subject to Rosenblum's continued employment through the closing date.","Rosenblum holds dual roles as Acting CEO and Executive VP/CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000148","json":"https://secwatch.observer/filing/0001615219-25-000148.json","markdown":"https://secwatch.observer/filing/0001615219-25-000148.md","text":"https://secwatch.observer/filing/0001615219-25-000148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/0001615219-25-000148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000148/flks-20251021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:02:10.646213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}